These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

629 related items for PubMed ID: 32998736

  • 21. Comparing clinical outcomes in patients with type 2 diabetes mellitus after ischaemic stroke: Sodium-glucose cotransporter 2 inhibitors users versus non-users. A propensity score matching National Cohort Study.
    Chen TY, Lee HF, Chan YH, Chuang C, Li PR, Yeh YH, Su HC, See LC.
    Diabetes Obes Metab; 2024 Oct; 26(10):4501-4509. PubMed ID: 39134462
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors.
    Lin DS, Lee JK, Chen WJ.
    Diabetologia; 2021 Sep; 64(9):1949-1962. PubMed ID: 34195865
    [Abstract] [Full Text] [Related]

  • 24. Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes.
    Zhou J, Liu X, Chou OH, Li L, Lee S, Wong WT, Zhang Q, Chang C, Liu T, Tse G, Jing F, Cheung BMY.
    Rheumatology (Oxford); 2023 Apr 03; 62(4):1501-1510. PubMed ID: 36066415
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong.
    Mui JV, Li L, Chou OHI, Azfar N, Lee A, Hui J, Lee S, Tse G, Zhou J.
    Acta Diabetol; 2023 Jul 03; 60(7):917-927. PubMed ID: 37000300
    [Abstract] [Full Text] [Related]

  • 30. Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study.
    Birkeland KI, Bodegard J, Banerjee A, Kim DJ, Norhammar A, Eriksson JW, Thuresson M, Okami S, Ha KH, Kossack N, Mamza JB, Zhang R, Yajima T, Komuro I, Kadowaki T.
    Diabetes Obes Metab; 2021 Jan 03; 23(1):75-85. PubMed ID: 32893440
    [Abstract] [Full Text] [Related]

  • 31. Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and the Incidence of Acute Kidney Injury in Taiwan.
    Chung MC, Hung PH, Hsiao PJ, Wu LY, Chang CH, Hsiao KY, Wu MJ, Shieh JJ, Huang YC, Chung CJ.
    JAMA Netw Open; 2023 Feb 01; 6(2):e230453. PubMed ID: 36811856
    [Abstract] [Full Text] [Related]

  • 32. Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease.
    Lim J, Hwang IC, Choi HM, Yoon YE, Cho GY.
    PLoS One; 2022 Feb 01; 17(10):e0269414. PubMed ID: 36251654
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. The impact of sodium-glucose co-transporter-2 inhibitors on dementia and cardiovascular events in diabetic patients with atrial fibrillation.
    Chen YY, Chang HC, Lin YJ, Chien KL, Hsieh YC, Chung FP, Lin CH, Lip GYH, Chen SA.
    Diabetes Metab Res Rev; 2024 Feb 01; 40(2):e3775. PubMed ID: 38340046
    [Abstract] [Full Text] [Related]

  • 35. Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study.
    Sütő G, Molnár GA, Rokszin G, Fábián I, Kiss Z, Szekanecz Z, Poór G, Jermendy G, Kempler P, Wittmann I.
    BMJ Open Diabetes Res Care; 2021 Jan 01; 9(1):. PubMed ID: 33472796
    [Abstract] [Full Text] [Related]

  • 36. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58.
    Bonaca MP, Wiviott SD, Zelniker TA, Mosenzon O, Bhatt DL, Leiter LA, McGuire DK, Goodrich EL, De Mendonca Furtado RH, Wilding JPH, Cahn A, Gause-Nilsson IAM, Johanson P, Fredriksson M, Johansson PA, Langkilde AM, Raz I, Sabatine MS.
    Circulation; 2020 Aug 25; 142(8):734-747. PubMed ID: 32795086
    [Abstract] [Full Text] [Related]

  • 37. Second-Line Pharmaceutical Treatments for Patients with Type 2 Diabetes.
    Vashisht R, Patel A, Dahm L, Han C, Medders KE, Mowers R, Byington CL, Koliwad SK, Butte AJ.
    JAMA Netw Open; 2023 Oct 02; 6(10):e2336613. PubMed ID: 37782497
    [Abstract] [Full Text] [Related]

  • 38. Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in South Korea: a nationwide cohort study.
    Jeong HE, Park S, Noh Y, Bea S, Filion KB, Yu OHY, Jang SH, Cho YM, Yon DK, Shin JY.
    BMC Med; 2023 Feb 10; 21(1):47. PubMed ID: 36765407
    [Abstract] [Full Text] [Related]

  • 39. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
    Patorno E, Pawar A, Franklin JM, Najafzadeh M, Déruaz-Luyet A, Brodovicz KG, Sambevski S, Bessette LG, Santiago Ortiz AJ, Kulldorff M, Schneeweiss S.
    Circulation; 2019 Jun 18; 139(25):2822-2830. PubMed ID: 30955357
    [Abstract] [Full Text] [Related]

  • 40. Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors, and Risk of Hospitalization.
    Lyu B, Grams ME, Chang A, Inker LA, Coresh J, Shin JI.
    Am J Cardiol; 2022 Feb 15; 165():124-130. PubMed ID: 34937658
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.